title: Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.
abstract: Extending our previous analyses to the most recently described monoclonal broadly neutralizing antibodies (bNAbs), we confirmed a drift of HIV-1 clade B variants over 2 decades toward higher resistance to bNAbs targeting almost all the identified gp120-neutralizing epitopes. In contrast, the sensitivity to bNAbs targeting the gp41 membrane-proximal external region remained stable, suggesting a selective pressure on gp120 preferentially. Despite this evolution, selected combinations of bNAbs remain capable of neutralizing efficiently most of the circulating variants.
authors.affiliation: Université François Rabelais, Inserm U966, Tours, France.
authors.forename: M
authors.initials: M
authors.lastname: Bouvin-Pley
authors.affiliation: Université François Rabelais, Inserm U966, Tours, France.
authors.forename: M
authors.initials: M
authors.lastname: Morgand
authors.affiliation: Université Paris Sud, CESP Inserm U1018, Paris, France AP-HP Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.
authors.forename: L
authors.initials: L
authors.lastname: Meyer
authors.affiliation: Université Paris Sud, CESP Inserm U1018, Paris, France AP-HP Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.
authors.forename: C
authors.initials: C
authors.lastname: Goujard
authors.affiliation: Université François Rabelais, Inserm U966, Tours, France.
authors.forename: A
authors.initials: A
authors.lastname: Moreau
authors.affiliation: Laboratory of Humoral Response to Pathogens, Department of Immunology, Institut Pasteur, Paris, France.
authors.forename: H
authors.initials: H
authors.lastname: Mouquet
authors.affiliation: Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA.
authors.forename: M
authors.initials: M
authors.lastname: Nussenzweig
authors.affiliation: Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York, USA.
authors.forename: C
authors.initials: C
authors.lastname: Pace
authors.affiliation: Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York, USA.
authors.forename: D
authors.initials: D
authors.lastname: Ho
authors.affiliation: California Institute of Technology, Pasadena, California, USA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Bjorkman
authors.affiliation: CRCM, Inserm U1068, Institut Paoli-Calmettes, CNRS UMR7258, Marseille, France.
authors.forename: D
authors.initials: D
authors.lastname: Baty
authors.affiliation: CRCM, Inserm U1068, Institut Paoli-Calmettes, CNRS UMR7258, Marseille, France.
authors.forename: P
authors.initials: P
authors.lastname: Chames
authors.affiliation: Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: M
authors.initials: M
authors.lastname: Pancera
authors.affiliation: Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: P D
authors.initials: PD
authors.lastname: Kwong
authors.affiliation: Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA International AIDS Vaccine Initiative Neutralizing Antibody Center, La Jolla, California, USA.
authors.forename: P
authors.initials: P
authors.lastname: Poignard
authors.affiliation: Université François Rabelais, Inserm U966, Tours, France Laboratoire de Bactériologie-Virologie and Centre National de Reference du VIH, CHU Bretonneau, Tours, France.
authors.forename: F
authors.initials: F
authors.lastname: Barin
authors.affiliation: Université François Rabelais, Inserm U966, Tours, France braibant@med.univ-tours.fr.
authors.forename: M
authors.initials: M
authors.lastname: Braibant
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D057134:Antibodies, Neutralizing / Q000276:immunology*; D058872:Epidemics; D040961:Genetic Drift; D015483:HIV Antibodies / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology*; D015700:HIV Envelope Protein gp41 / Q000235:genetics / Q000276:immunology; D015658:HIV Infections / Q000453:epidemiology / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D008297:Male; D051379:Mice; D009500:Neutralization Tests
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; C514793:gp120 protein, Human immunodeficiency virus 1; C514787:gp41 protein, Human immunodeficiency virus 1